{"entity":{"id":"nct07381764","kind":"trial","name":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","aka":["ROMANCE - GOIM"],"tldr":"A phase 2 trial of cetuximab, bevacizumab (glioblastoma use), fOLFIRI (5-FU, leucovorin, irinotecan) and trifluridine/tipiracil in colorectal cancer, run by Gruppo Oncologico Italia Meridionale, now recruiting.","summary":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\" is a phase 2, randomised interventional study registered as NCT07381764 by Gruppo Oncologico Italia Meridionale, with a registry enrolment figure of 150 participants, started 2026-03-20 and due to reach its primary completion in 2031-03-30. Interventions recorded: Erbitux (Cetuximab); Bevacizumab; Irinotecan; Trifluridine/tipiracil. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: \"Diagnosis of histologically or cytologically confirmed colorectal cancer\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07381764","url":"https://clinicaltrials.gov/study/NCT07381764"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody","mrd-testing","topoisomerase-inhibitors"],"targets":[],"drugs":["cetuximab","bevacizumab-glioma","folfiri","trifluridine-tipiracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07381764","phase":"2","setting":"ROMANCE GOIM Study: A Phase II, Open Label, Multicenter Trial Investigating Irinotecan Plus Cetuximab Rechallenge Compared With Trifluridine/Tipiracil Plus Bevacizumab as Third Line Treatment in Circulating Tumor DNA Molecularly Selected Metastatic Colorectal Cancer","sponsor":"Gruppo Oncologico Italia Meridionale","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07381764/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}